The Efficacy of Preemptive Milrinone or Amrinone Therapy in Patients Undergoing Coronary Artery Bypass Grafting

45 patients undergoing coronary artery bypass grafting

Milrinone (50 microg/kg bolus plus 0.5 microg/kg/min infusion for 10 h) or amrinone (1.5 mg/kg bolus plus 10 microg/kg/min infusion for 10 h) administered at release of aortic cross-clamp

Placebo administered at release of aortic cross-clamp

Hemodynamic variables (stroke volume index, oxygen transport index, heart rate), dopamine requirement, and laboratory values (serum lactate, alanine and aspartate aminotransferase, lactate dehydrogenase, creatinine kinase, C-reactive protein, and glucose) in the postoperative periodsurrogate